BioCentury
ARTICLE | Finance

Regulatory milestones

Highlights of weekly biotech stock moves

July 19, 2010 7:00 AM UTC

Amgen Inc. (NASDAQ:AMGN) shed $0.39 to $52.17 last week after FDA accepted for filing and granted Priority Review to a BLA for denosumab to treat bone metastases to reduce skeletal related events (SREs) in cancer patients. The PDUFA date is Nov. 18.

Denosumab is a human mAb targeting receptor activator of NF-kappa B ligand (RANKL; TNFSF11). It already is approved in the U.S. as Prolia to treat osteoporosis in postmenopausal women...